The association of glycated hemoglobin A1c with coronary artery disease,myocardial infarction,and severity of coronary lesions

Abstract

Glycated hemoglobin A1c (HbA1c) has been recognized as a predictor of cardiovascular events. However, the relationship between HbA1c and coronary artery disease (CAD) in the Chinese population has yet to be systematically explored. In addition, factors associated with HbA1c were generally analyzed linearly, thereby failing to appreciate more complex nonlinear associations. The study aimed to evaluate the relationship between the HbA1c value and the presence and severity of coronary artery stenosis. A total of 7192 consecutive patients who underwent coronary angiography were enrolled. Their biological parameters, including HbA1c, were measured. The severity of coronary stenosis was evaluated using Gensini score. After correcting for baseline confounding factors, a multivariate logistic regression analysis was used to evaluate the relationship between HbA1c and CAD severity. Restricted cubic splines were applied to explore the relation of HbA1c with the presence of CAD, myocardial infarction (MI), and the severity of coronary lesions. HbA1c was significantly associated with the presence and severity of CAD in patients without diagnosed diabetes (odds ratio: 1.306, 95% confidence interval: 1.053–1.619, p = 0.015). Spline analysis showed a U-shaped association of HbA1c with the presence of MI. Both HbA1c > 7.2% and HbA1c < 5.7% were associated with the presence of MI. In conclusion, HbA1c value was highly associated with the severity of coronary artery stenosis in the whole study population, and in CAD patients without diagnosed diabetes. Compared with patients with HbA1c levels between 6.0% and 7.0%, HbA1c < 5.7% and HbA1c > 7.2% were associated with higher presence of MI.

Keywords

Coronary artery disease HbA1c myocardial infarction Gensini score

Get full access to this article

View all access options for this article.

References

Barr

Zimmet

Welborn

, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian diabetes, obesity, and lifestyle study (AusDiab). Circulation 2007; 116: 151–157.

Stamler

Vaccaro

Neaton

, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabet Care 1993; 16: 434–444.

Unwin

Shaw

Zimmet

, et al. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med: J Brit Diabet Assoc 2002; 19: 708–723.

DECODE Study Group European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabet Care 2003; 26: 688–696.

Kurihara

Takano

Yamamoto

, et al. Impact of prediabetic status on coronary atherosclerosis: a multivessel angioscopic study. Diabet Care 2013; 36: 729–733.

Shrom

Sarwat

Ilag

, et al. Does A1c consistently reflect mean plasma glucose? J Diabet 2010; 2: 92–96.

Currie

Peters

Tynan

, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481–489.

Stratton

Adler

Neil

, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical research ed) 2000; 321: 405–412.

Khaw

Wareham

Glycated hemoglobin as a marker of cardiovascular risk. Curr opin lipidol 2006; 17: 637–643.

10.

Gerstein

Miller

Byington

, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559.

11.

Huang

Liu

Moffet

, et al. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabet Care 2011; 34: 1329–1336.

12.

Baber

Azzalini

Masoomi

, et al. Hemoglobin A1c and cardiovascular outcomes following percutaneous coronary intervention: insights from a large single-center registry. JACC Cardiovasc Interv 2021; 14: 388–397.

13.

Ewid

Sherif

Billah

SMB

, et al. Glycated hemoglobin predicts coronary artery disease in non-diabetic adults. BMC Cardiovasc Disord 2019; 19: 309.

14.

Zhou

, et al. Glycated albumin is more closely correlated with coronary artery disease than 1,5-anhydroglucitol and glycated hemoglobin A1c. Cardiovasc Diabetol 2015; 14: 16.

15.

Shen

, et al. Glycated albumin is superior to hemoglobin A1c for evaluating the presence and severity of coronary artery disease in type 2 diabetic patients. Cardiology 2012; 123: 84–90.

16.

Gao

Deng

, et al. Eosinophils count in peripheral circulation is associated with coronary artery disease. Atherosclerosis 2019; 286: 128–134.

17.

Liu

Wan

Zhao

, et al. Adjustment of the GRACE score by HemoglobinA1c enables a more accurate prediction of long-term major adverse cardiac events in acute coronary syndrome without diabetes undergoing percutaneous coronary intervention. Cardiovasc Diabetol 2015; 14: 110.

18.

Mancia

Fagard

Narkiewicz

, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J 2013; 34: 2159–2219.

19.

Rydén

Grant

Anker

, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC) and developed in collaboration with the European association for the study of diabetes (EASD). Eur Heart J 2013; 34: 3035–3087.

20.

Gensini

GG.

A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.

21.

Weiwei

Runlin

Lisheng

, et al. Outline of the report on cardiovascular diseases in China, 2014. Eur Heart J Suppl: J Eur Soc Cardiol 2016; 18: F2–F11.

22.

Wei

Gaskill

Haffner

, et al. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio heart study. Diabet Care 1998; 21: 1167–1172.

23.

Cowie

Harris

MI.

Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 1998; 21: 1138–1145.

24.

Haffner

Lehto

Rönnemaa

, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234.

25.

Gerstein

Pogue

Mann

, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005; 48: 1749–1755.

26.

Zhang

Wang

, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing diabetes prevention study: a 23-year follow-up study. Lancet Diabet Endocrinol 2014; 2: 474–480.

27.

Eitel

Hintze

de Waha

, et al. Prognostic impact of hyperglycemia in nondiabetic and diabetic patients with ST-elevation myocardial infarction: insights from contrast-enhanced magnetic resonance imaging. Circ Cardiovasc Imaging 2012; 5: 708–718.

28.

Cohen

Ziyadeh

Chen

Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J Lab Clin Med 2006; 147: 211–219.

29.

Flyvbjerg

Denner

Schrijvers

, et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004; 53: 166–172.

30.

Andreozzi

Gastaldelli

Mannino

, et al. Increased carotid intima-media thickness in the physiologic range is associated with impaired postprandial glucose metabolism, insulin resistance and beta cell dysfunction. Atherosclerosis 2013; 229: 277–281.

31.

Nathan

Turgeon

Regan

Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 2007; 50: 2239–2244.

32.

Selvin

Marinopoulos

Berkenblit

, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421–431.

33.

Choi

Benzie

, et al. Acute hyperglycemia and oxidative stress: direct cause and effect? Free Radic Biol Med 2008; 44: 1217–1231.

34.

Koenig

Khuseyinova

Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007; 27: 15–26.

35.

Engoren

Schwann

Arslanian-Engoren

, et al. U-shape association between hemoglobin A1c and late mortality in patients with heart failure after cardiac surgery. Am J Cardiol 2013; 111: 1209–1213.

36.

Abraira

Colwell

Nuttall

, et al. Cardiovascular events and correlates in the veterans affairs diabetes feasibility trial. Veterans affairs cooperative study on glycemic control and complications in type II diabetes. Arch Intern Med 1997; 157: 181–188.

37.

Ray

Seshasai

Wijesuriya

, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765–1772.

38.

Turnbull

Abraira

Anderson

, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288–2298.

39.

Rodbard

Blonde

Braithwaite

, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13: 1–68.

40.

Brown

Mangione

Saliba

, et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51: S265–S280.

41.

Rezende

Hlatky

Hueb

, et al. Association of longitudinal values of glycated hemoglobin with cardiovascular events in patients with type 2 diabetes and multivessel coronary artery disease. JAMA Netw Open 2020; 3: e1919666.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.26 MB